Prescribing Information [External link]

Expert on Demand in Endometrial Cancer

The Expert on Demand programme at MSD provides an exciting opportunity for you and your MDT to connect with Experts in endometrial cancer at a time that works for you.

How to sign up?

  • Choose your module
  • Complete the form below to express your interest
  • You will be contacted by your local MSD representative to arrange a suitable time and date

Read more about the available module in endometrial cancer below:

Enhancing treatment options for patients with pMMR and dMMR primary advanced or recurrent endometrial cancer.

Learning Objectives :

Speakers

Headshot of Dr. Rowan Miller, Consultant Medical Oncologist.

Dr Rowan Miller

University College London and St Bartholomew’s Hospitals

Biography

Dr Rowan Miller is a Consultant Medical Oncologist specialising in gynae-oncology and early phase clinical trials at University College London and St Bartholomew’s hospitals. Her research interests include novel therapies for gynaecological cancer and utilising genomics and biomarkers to guide therapy in patients within early phase trials.

Dr Miller completed her undergraduate training at the University of Oxford and clinical training at Guy’s and St Thomas’ Hospitals, London. She trained in Medical Oncology at University College London and was subsequently awarded a Cancer Research UK Fellowship and attained a PhD from the Institute of Cancer Research. Her PhD evaluated novel therapies for patients with clear cell ovarian cancer.

Dr Miller is involved in several clinical trials and basic science research was a member of the European Society of Medical Oncology (ESMO) Personalized Medicine and Translational Research Committee. Dr Miller is a member of the 2025 ESMO Development Therapeutic Scientific Committee and is faculty for the EORTC-ESMO-AACR Methods in Clinical Cancer Research (MCCR) workshop.

Headshot of Dr. Alison Stillie, Consultant Clinical Oncologist.

Dr Alison Stillie

Edinburgh Cancer Centre

Biography

Dr Alison Stillie is a Consultant Clinical Oncologist specialising in gynaecological cancers at the Edinburgh Cancer Centre. She is Associate Director of Medical Education at the Western General Hospital and an Honorary Senior Lecturer at the University of Edinburgh. Dr Stillie is actively involved in clinical trials, medical education, and national oncology leadership, including her role as Vice Chair of the Royal College of Radiologists FRCR Part 2B examination board.

KEYTRUDA (pembrolizumab), in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults. 1

Please refer to the SmPC for further information before making any prescribing decisions.

To register your interest in Expert on Demand please complete the form below:

Read about the modules here

MSD will only use this information for the purpose of responding to your inquiry and it will not be stored for any other use. MSD will not pass your information on to a third party organisation. This form is not intended for the reporting of adverse events or medical information.The reporting form and MSD Medical Information contact details can be found at the end of this page.

This field is for validation purposes and should be left unchanged.

Reference

  1. KEYTRUDA Summary of Product Characteristics.

Supporting documentation

Prescribing Information [External link]

GB-END-00082 | Date of Preparation: November 2025